Pacific Biosciences of California, Inc. (PACB): Price and Financial Metrics

Pacific Biosciences of California, Inc. (PACB): $8.50

0.11 (+1.31%)

POWR Rating

Component Grades








PACB Price/Volume Stats

Current price $8.50 52-week high $14.55
Prev. close $8.39 52-week low $5.74
Day low $8.43 Volume 3,966,400
Day high $8.77 Avg. volume 4,116,156
50-day MA $7.78 Dividend yield N/A
200-day MA $10.47 Market Cap 2.27B

PACB Stock Price Chart Interactive Chart >


  • PACB scores best on the Growth dimension, with a Growth rank ahead of 65.64% of US stocks.
  • The strongest trend for PACB is in Stability, which has been heading down over the past 177 days.
  • PACB ranks lowest in Stability; there it ranks in the 8th percentile.

PACB Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for PACB is 0.22 -- better than just 18.29% of US stocks.
  • With a price/sales ratio of 14.01, PACIFIC BIOSCIENCES OF CALIFORNIA INC has a higher such ratio than 92.5% of stocks in our set.
  • Revenue growth over the past 12 months for PACIFIC BIOSCIENCES OF CALIFORNIA INC comes in at 23.76%, a number that bests 80.24% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PACIFIC BIOSCIENCES OF CALIFORNIA INC are ROIV, GANX, AKTS, IPWR, and LASR.
  • Visit PACB's SEC page to see the company's official filings. To visit the company's web site, go to

PACB Valuation Summary

  • PACB's EV/EBIT ratio is -9.3; this is 173.23% lower than that of the median Healthcare stock.
  • Over the past 159 months, PACB's price/earnings ratio has gone down 0.3.

Below are key valuation metrics over time for PACB.

Stock Date P/S P/B P/E EV/EBIT
PACB 2023-11-20 13.5 3.0 -7.4 -9.3
PACB 2023-11-17 13.3 2.9 -7.3 -9.2
PACB 2023-11-16 12.0 2.7 -6.6 -8.4
PACB 2023-11-15 12.3 2.7 -6.8 -8.6
PACB 2023-11-14 11.4 2.5 -6.2 -8.1
PACB 2023-11-13 10.2 2.3 -5.6 -7.4

PACB Growth Metrics

    Its 2 year price growth rate is now at 80.53%.
  • Its 4 year net income to common stockholders growth rate is now at 33.39%.
  • Its 3 year revenue growth rate is now at 77.95%.
Over the past 15 months, PACB's revenue has gone up $31,145,000.

The table below shows PACB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 136.97 -234.353 -299.193
2022-06-30 139.546 -211.956 -205.68
2022-03-31 134.689 -167.105 -175.287
2021-12-31 130.513 -111.18 -181.223
2021-09-30 121.63 -93.735 -36.959
2021-06-30 105.825 -70.887 -77.209

PACB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PACB has a Quality Grade of C, ranking ahead of 52.82% of graded US stocks.
  • PACB's asset turnover comes in at 0.132 -- ranking 67th of 75 Measuring and Control Equipment stocks.
  • TMO, PKI, and PRPO are the stocks whose asset turnover ratios are most correlated with PACB.

The table below shows PACB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.132 0.427 -0.085
2021-03-31 0.169 0.412 -0.129
2020-12-31 0.271 0.413 0.185
2020-09-30 0.355 0.428 -0.409
2020-06-30 0.445 0.411 -0.473
2020-03-31 0.515 0.410 -0.412

PACB Price Target

For more insight on analysts targets of PACB, see our PACB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $45.75 Average Broker Recommendation 1.6 (Moderate Buy)

Pacific Biosciences of California, Inc. (PACB) Company Bio

Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company was formerly known as Nanofluidics, Inc. The company was founded in 2000 and is based in Menlo Park, California.

PACB Latest News Stream

Event/Time News Detail
Loading, please wait...

PACB Latest Social Stream

Loading social stream, please wait...

View Full PACB Social Stream

Latest PACB News From Around the Web

Below are the latest news stories about PACIFIC BIOSCIENCES OF CALIFORNIA INC that investors may wish to consider to help them evaluate PACB as an investment opportunity.

Why Is IQVIA (IQV) Up 12.4% Since Last Earnings Report?

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 1, 2023

Compared to Estimates, Pacific Biosciences (PACB) Q3 Earnings: A Look at Key Metrics

The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Yahoo | November 10, 2023

PacBio to Present at Upcoming Investor Conferences

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:

Yahoo | November 9, 2023

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the creation of the HiFi Solves consortium. This global consortium brings together researchers from 15 leading genomics research institutions across 11 countries to study the value HiFi-based human genome sequencing may have in clinical research applications and to further our understanding of genetic diseases. These institutions will collaborate to develop and share best practices o

Yahoo | November 2, 2023

PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partners to PacBio Compatible

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the addition of two tertiary analysis partners to PacBio Compatible. Geneyx and Golden Helix will enable PacBio customers to leverage PacBio HiFi data for disease research with the Revio, Sequel II and IIe sequencing systems.

Yahoo | November 1, 2023

Read More 'PACB' Stories Here

PACB Price Returns

1-mo 23.55%
3-mo -18.19%
6-mo -38.32%
1-year -8.60%
3-year -60.47%
5-year 12.88%
YTD 3.91%
2022 -60.02%
2021 -21.13%
2020 404.67%
2019 -30.54%
2018 180.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!